6 TECH OUTLOOKOctober - 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comCancer­a disease that baffles everyone involved, an ailment where the future looks bleak! For centuries, science has made relentless efforts to find a perfect cure for cancer. However, a miracle is still awaited! But, years of evolution in medical realm and researches by eminent scientists have introduced immunotherapy as the ray of hope in paving the way for more effective clinical responses in cancer patients. The last couple of years have highlighted cancer immunotherapy as the knight in shining armour, but more work remains to be done in upcoming years despite this progress. In the wake of new technologies, future immunotherapy will incorporate AI and ML in identifying precision medicines for specific patients, resulting in an increased recovery rate. 3D cell culture models will profoundly impact the quality of readouts and, more profoundly, emphasise the growth of tumours. What looks evident is that the future of cancer immunotherapy will rely on the combination of selective cancer vaccines and checkpoint inhibitors, or other means of relieving immune suppression associated with a tumour. We can expect healthcare organisations to invest more in predictive and prognostic biomarkers that can help them understand intricate interactions in the immune systems and answer compelling questions like: why does immunotherapy response vary from patient to patient?There is no doubt that the immunotherapy sector is on the fast track of evolution. Standing at the cusp of innovative strategies and technologies, there are a wide range of solution providers that offer the latest immunotherapy technologies and capabilities best suited for the next generation healthcare needs. To help clients steer through the best-of-breed companies, Pharma Tech Outlook has compiled a list of Top 10 Immunotherapy Solution Providers in Europe - 2020. These organisations are transforming the immunotherapy landscape at the cloverleaf of various disruptive diagnostic methodologies and treatments. Besides, the magazine comprises insights from subject-matter experts, CIOs, and CXOs in the healthcare sector on the latest industry trends, best practices, recent innovations, and highlights their expertise.Let us know your thoughts!AI Will Personalise ImmunotherapyCopyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.OCTOBER - 05 - 2020, Vol 06 - Issue 21 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405John GothamTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >